"Introduction
... The first mass vaccination program started in early December 2020, and as of 14 October 2021, 6,495,672,032 doses of vaccine have been administered globally. By 3 June 2021, the World Health Organization (WHO) announced that the AstraZeneca/Oxford, Johnson and Johnson/Janssen (JnJ), Moderna, Pfizer/BioNTech, Sinopharm, and Sinovac vaccines are safe and effective...
Cardiovascular Complications of SARS-CoV-2 Vaccines
Severe side effects of vaccines may appear in some individuals vaccinated in mass vaccination programs. Also, given the short development time and the novelty of the technologies adopted, these vaccines may have serious side effects that will only be revealed after some time. One potential mechanism is the free-floating spike proteins, synthesized by cells targeted by the vaccines, that circulate in the blood systematically interacting with angiotensin converting enzyme 2 (ACE2) receptors. These reactions may ultimately lead to platelet aggregation, thrombosis, and inflammation. In this review, the potential cardiovascular complications of SARS-CoV-2 vaccines will be discussed...
Conclusion
As described in this article, cardiovascular complications (i.e., thromboembolic events, myocarditis/pericarditis, Takotsubo cardiomyopathy, arrhythmias, and myocardial infarction) in individuals following COVID-19 vaccination have been reported recently; however, for most of the complications reports, the association between vaccination and the complications has not been proved."
© The Author(s) 2021
This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material.
To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.